KLK3 and prostate cancer: Long-term responses at PSA levels <0.1 ng/ml occurred in rapidly progressive prostate cancer with PSA doubling times <3 months using combined transcriptional modulation, dexamethasone and pioglitazone in addition to metronomic low-dose chemotherapy.